Novadiscovery
NOVA is a leading Healthtech company which simulates in silico clinical trials in virtual patient populations for bio-pharma companies with a need to accelerate and de-risk their R&D. With over a decade of experience and multiple commercial projects with biotech and pharma companies, NOVA has developed a unique in silico clinical trial simulation platform called JINKO. With BioModeling, Artificial Intelligence and Virtual Populations at the heart of NOVA’s innovative approach, the platform takes its name from the fortunate homonymic collision of the Japanese words for ‘artificial’ (人工, jinkō) and ‘population’ (人口, jinkō).
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2010
About Us
NOVA is a leading Healthtech company which simulates in silico clinical trials in virtual patient populations for bio-pharma companies with a need to accelerate and de-risk their R&D.
With over a decade of experience and multiple commercial projects with biotech and pharma companies, NOVA has developed a unique in silico clinical trial simulation platform called Jinkō®.
With BioModeling, Artificial Intelligence and Virtual Populations at the heart of NOVA’s innovative approach, the platform takes its name from the fortunate homonymic collision of the Japanese words for ‘artificial’ (人工, jinkō) and ‘population’ (人口, jinkō).
We accelerate and de-risk clinical development.
In doing so, we bring speed and efficiency gains to pharmaceutical and biotech companies.
Our Mission
Our mission is to enable improved outcomes for patients.
Our modeling platform allows for the narrowing of inclusion criteria to target the most responsive patients in trials, avoiding unnecessary enrollment of non-responsive patients and accelerating research in orphan indications with limited numbers of patients by leveraging virtual patients.
Core Values
Our values and cultural attributes form the bedrock of our success. We hire the best and brightest, and we chose our team members as much for their attitude as their aptitude. Individuals on our team combine deep domain expertise with a drive to continuously improve and help others and demonstrate an ownership mentality.
We foster a culture of transparent communication to build trust and accountability. NOVA’s cultural attributes are: integrity, emergent leadership, comfort with ambiguity and intellectual humility.
History
NOVA’s vision of in silico clinical trials becoming the third pillar of the drug R&D paradigm - as a powerful support and not a substitute to more conventional in vitro and in vivo experiments - was born in the mind of our cofounder Prof. Jean-Pierre Boissel in the early nineties.
In 2008, Jean-Pierre had recently retired from a career in academic research in clinical pharmacology when his youngest son. François-Henri returned from Tokyo after his Principal Finance group was wound down at Lehman Brothers.
They eventually launched in 2010, with the support of Fred Cogny and other friends and family investors, what was to become an incredibly rewarding adventure.